Business
Inaphaea BioLabs Operational Update
Inaphaea BioLabs Operational Update.
About this update from Valirx Plc
[{"type":"text","content":"\n\nValiRx PLC\n(\"ValiRx\" or the \"Company\")\nInaphaea BioLabs Operational Update\nLondon, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces an operational update from the Company's wholly owned subsidiary, Inaphaea BioLabs Limited (\"Inaphaea\").\nInaphaea has entered into an agreement with the Virtual CRO services company OncoBone Limited (\"OncoBone\") whereby clients of OncoBone can access Inaphaea services. OncoBone offers a service to virtual biotech and other biopharma clients whereby OncoBone designs and commissions pre-clinical work on behalf of the client. To conduct the laboratory work, OncoBone engages with a range of pre-clinical Contract Research Organisations (\"CROs\") to execute on the experimental designs that OncoBone has developed. Inaphaea is now confirmed as an OncoBone supplier of cell-based assays.\nAdditionally, Inaphaea is pleased to report that the cell-based assay services are now listed on scientist.com, a database of CROs that can be used by biotechnology and pharmaceutical companies to search for scientific capabilities.\nDr Suzy Dilly, CEO at ValiRx explains \"This operational update demonstrates the progress made by Inaphaea towards generating contract revenues. We're particularly excited by the prospect of working with OncoBone due to the innovative nature of their Virtual CRO service.\"\nThe Directors of the Company take responsibility for this announcement.\n \nFor more information, please contact:\n \n\n\n\nValiRx plc\n \nDr Suzanne Dilly, CEO\n \n \nInaphaea BioLabs Limited\n \nDr Andrew Carnegie, Head of Strategic Commercial Development\n \n\n\nTel: +44 (0) 2476 796496\nwww.valirx.com\[email protected]\n \n \nwww.inaphaea.com\n \[email protected]\n \n\n\n\n\nV Formation (Public Relations)\n \nLucy Wharton - Senior PR Executive\nSue Carr - Director\n \n\n\n+44 (0) 115 787 0206\nwww.vformation.biz\n \[email protected]\[email protected]\n\n\n\n\nCenkos Securities plc (Joint Broker)\n \nDale Bellis/Michael Johnson (Sales)\n \nCallum Davidson/Giles Balleny (Corporate Finance)\n\n\nTel: +44 (0) 20 7397 8900\n\n\n\n\nTurner Pope Investments (Joint Broker)\nJames Pope / Andy Thacker \n\n\nT...